Gsk (GSK) Research & Development (2009 - 2026)
Gsk (GSK) posted Research & Development of $2.66 billion for the quarter ended Sep 30, 2026, up 16.9% from $2.28 billion a year earlier but down 42.7% from the prior quarter.
Powered by 
Analysis
Gsk (GSK) Research & Development (2009 - 2026) Analysis & Trends
For the trailing twelve months through Sep 30, 2026, Research & Development at Gsk was $19.61 billion, up 30.4% year-over-year; for the year ended Dec 31, 2025, it was $9.92 billion, up 21.3% from the prior year.
- Annual Research & Development has increased for three consecutive years, with a five-year compound annual growth rate of 10.0% (years ended Dec 2020 to Dec 2025).
- In prior years, Gsk's Research & Development was $8.18 billion in the year ended Dec 31, 2024 (+5.7%), $7.74 billion in the year ended Dec 31, 2023 (+14.0%), $6.79 billion in the year ended Dec 31, 2022 (-1.6%) and $6.91 billion in the year ended Dec 31, 2021 (+12.2%).
- Quarterly Research & Development has run from a low of $1.48 billion in the quarter ended Mar 31, 2022 to a high of $10.01 billion in the quarter ended Dec 31, 2025 over five years.
- On a year-over-year basis, Research & Development has increased in each of the last eight quarters, with growth averaging 25.9% over the last eight quarters.
- The strongest year-over-year quarter for Research & Development in the past five years was the quarter ended Dec 31, 2022, with growth of 247.0%; the weakest was the quarter ended Sep 30, 2022, with a decline of 18.7%.
- According to Business Quant data, Research & Development for the three prior quarters was $4.65 billion (quarter ended Jun 30, 2026), $2.28 billion (quarter ended Mar 31, 2026) and $10.01 billion (quarter ended Dec 31, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.17 Bn | 1,237.79 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 660.04 Bn | 579.90 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 521.06 Bn | 494.17 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.60 Bn | 370.60 Bn | - | 4.54 Bn |
| 5 | Novartis Ag | 311.97 Bn | 285.20 Bn | - | - |
| 6 | Astrazeneca | 288.69 Bn | 262.37 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 252.29 Bn | 207.69 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 213.47 Bn | 213.47 Bn | - | 1.61 Bn |
| 9 | Pfizer | 173.68 Bn | 120.32 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Gsk | 100.27 Bn | 83.11 Bn | 8.73 Bn | 2.66 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 2.66 Bn |
| Jun 30, 2026 | 4.65 Bn |
| Mar 31, 2026 | 2.28 Bn |
| Dec 31, 2025 | 10.01 Bn |
| Sep 30, 2025 | 2.28 Bn |
| Jun 30, 2025 | 2.70 Bn |
| Mar 31, 2025 | 1.84 Bn |
| Dec 31, 2024 | 8.22 Bn |
| Sep 30, 2024 | 1.90 Bn |
| Jun 30, 2024 | 1.86 Bn |
| Mar 31, 2024 | 1.82 Bn |
| Dec 31, 2023 | 7.72 Bn |
| Sep 30, 2023 | 2.00 Bn |
| Jun 30, 2023 | 1.68 Bn |
| Mar 31, 2023 | 1.53 Bn |
| Dec 31, 2022 | 6.44 Bn |
| Sep 30, 2022 | 1.59 Bn |
| Jun 30, 2022 | 1.56 Bn |
| Mar 31, 2022 | 1.48 Bn |
| Dec 31, 2021 | 1.85 Bn |
API Access
Gsk Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=GSK&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "GSK", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=GSK&period=max&api_key=YOUR_API_KEY");
const data = await res.json();